Corvel (CRVL) stock price is $82.23, down 1.12% on the day, as of Nov 9, 2026. It has a market cap of $4.16Bn and a P/E ratio of 34.22, and is classified in the Managed Care industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap4.16 Bn
P/E34.22
FCF (Yr)110.28 Mn
ROA (Yr)18.56
EV to EBIT19.67
Net Income (Yr)110.34 Mn
Enterprise Value3.17 Bn
Add ratio to table…
About
CorVel applies technology including artificial intelligence, machine learning and natural language processing to enhance the management of episodes of care and related health care costs. The company partners with employers, third party administrators, insurance companies and government agencies to help manage medical costs of workers compensation, group health and auto insurance, and to monitor care quality for claimants. CorVel delivers its solutions three ways: as a fully…
CorVel applies technology including artificial intelligence, machine learning and natural language processing to enhance the management of episodes of care and related health care costs. The company partners with employers, third party administrators, insurance companies and government agencies to help manage medical costs of workers compensation, group health and auto insurance, and to monitor care quality for claimants. CorVel delivers its solutions three ways: as a fully integrated claims management program, as discrete standalone services, or as targeted add ons that enhance an existing client workflow. Integrated end to end bundled programs are designed primarily for buyers such as self insured employers who want a single turnkey partner. Individual modules and a la carte add ons tend to fit larger scale relationships where insurance carriers or third party administrators plug specific CorVel capabilities into a broader service stack. The company maintains a nationwide presence across a network of branches, with its Fort Worth Texas location serving as a central hub for operations.
CorVel generates revenue by providing its managed care and cost containment services to customers. The company’s primary revenue sources include fees for claims management, bill review, preferred provider network access, utilization management, case management, pharmacy services, directed care and Medicare related solutions. These services are delivered under various pricing arrangements such as per claim fees, transaction based charges or subscription models depending on the customer’s needs. CorVel serves a diverse customer base that includes employers, third party administrators, insurance carriers and government agencies seeking assistance with workers compensation, group health and auto liability claims. The firm’s revenue is not concentrated, with no single customer accounting for 10% or more of total sales in recent fiscal years.
Within the workers compensation and health care cost containment industry, CorVel competes with third party administrators, managed care organizations, large insurance carriers and numerous independent service providers. Many of these competitors possess greater financial and marketing resources, yet CorVel distinguishes itself through its proprietary technology platform that integrates artificial intelligence, machine learning and natural language processing to automate bill review and claims processing. The company’s nationwide network of over 1,200,000 providers in its preferred provider organization offers extensive coverage and depth of discount for clients. Proprietary tools such as the CareMC portal, the CERIS forensic review system and the Symbeo document management suite enhance operational efficiency and provide differentiated analytics. CorVel’s ability to offer both full program solutions and a la carte modules allows it to serve a wide range of client preferences, from turnkey partnerships to targeted enhancements of existing workflows. This flexibility, combined with a focus on local service delivery backed by national expertise, supports the company’s competitive position in the market.
CorVel’s customer base consists of insurers, third party administrators, self administered employers, government agencies, municipalities, state funds and other stakeholders in the health care industry. The company reports that no single customer accounted for 10% or more of revenue in recent fiscal years, although a few customers represent notable portions of accounts receivable. Services are provided to clients across all states and to businesses of varying sizes, from small employers to large multinational corporations. By maintaining a local branch network alongside a centralized headquarters, CorVel can deliver personalized service while leveraging national scale capabilities. The firm’s diversification helps mitigate reliance on any one sector or geographic region.
Sector:HealthcareSector rationaleCorVel provides managed care and cost containment services, specifically focusing on claims management, bill review, and utilization management for workers compensation and group health. Its revenue is derived from delivering these healthcare-related services to employers, insurance companies, and government agencies, which aligns with the Healthcare sector's 'Healthcare Services' industry.Industries:Managed CareManaged CarePrimaryCorVel provides managed care and cost containment services, including pharmacy services and preferred provider network access, to insurance companies and self-insured employers. Its revenue is derived from managing medical costs for workers compensation and group health, which aligns with the pharmacy-benefit management and managed-care fee structures described in H-18.Healthcare ServicesHealthcare ServicesSecondaryThe company provides case management and utilization management services to monitor care quality for claimants. These activities involve the coordination and management of outpatient healthcare services delivered through its network of over 1,200,000 providers.Classified using BQ-MICSCIK: 0000874866
Bull & bear
Investment Thesis
▲ Bull case
CRVL is positioned to capitalize on a fundamental shift in healthcare payer strategies from reactive claim correction to proactive payment accuracy, where its integrated CERIS platform delivers measurable value by reducing administrative burden and strengthening provider partnerships, a trend explicitly endorsed by management as accelerating demand for these capabilities, with new multiyear partnerships with top 10 national payers signaling entrenched customer commitment beyond transactional engagements, which management expects will contribute meaningfully to revenue and profit growth as these programs scale and mature, creating a durable tailwind that is not yet fully reflected in current valuation multiples given the company's consistent double-digit growth in Network Solutions and improving operating leverage from automation initiatives.
The company's strategic advancement of prepaid solutions, which offer a significantly shorter revenue realization cycle of 1-2 months compared to 6+ months for postpaid services, is creating a more predictable and scalable revenue model supported by long-term contracts, a structural shift management highlighted as enhancing cash flow visibility and reducing working capital volatility, while maintaining comparable margin profiles, and this evolution is being further enabled by ongoing investments in AI and automation that augment workforce productivity without replacing human expertise, allowing claims professionals to focus on higher-value work, which directly addresses industry-wide labor constraints and positions CRVL to gain market share as payers prioritize intelligent platforms delivering consistent clinical and financial outcomes.
CRVL's robust financial profile—featuring a debt-free balance sheet, $233 million in cash, $66 million in free cash flow (up $7 million YoY), and improved operating margin of 15% (up 140 bps YoY)—combined with disciplined capital allocation through its share repurchase program (now having repurchased 69% of total shares outstanding at an average price of $7.70) signals strong confidence in intrinsic value and provides significant flexibility for strategic acquisitions or accelerated technological investment, particularly as management explicitly noted the balance sheet uniquely positions the company for accelerating product expansion and acquisition opportunities, a lever that could meaningfully accelerate growth beyond organic expectations if deployed toward adjacent technology-enabled claims management assets.
CRVL is positioned to capitalize on a fundamental shift in healthcare payer strategies from reactive claim correction to proactive payment accuracy, where its integrated CERIS platform delivers measurable value by reducing administrative burden and strengthening provider partnerships, a trend explicitly endorsed by management as accelerating demand for these capabilities, with new multiyear partnerships with top 10 national payers signaling entrenched customer commitment beyond transactional engagements, which management expects will contribute meaningfully to revenue and profit growth as these programs scale and mature, creating a durable tailwind that is not yet fully reflected in current valuation multiples given the company's consistent double-digit growth in Network Solutions and improving operating leverage from automation initiatives.
The company's strategic advancement of prepaid solutions, which offer a significantly shorter revenue realization cycle of 1-2 months compared to 6+ months for postpaid services, is creating a more predictable and scalable revenue model supported by long-term contracts, a structural shift management highlighted as enhancing cash flow visibility and reducing working capital volatility, while maintaining comparable margin profiles, and this evolution is being further enabled by ongoing investments in AI and automation that augment workforce productivity without replacing human expertise, allowing claims professionals to focus on higher-value work, which directly addresses industry-wide labor constraints and positions CRVL to gain market share as payers prioritize intelligent platforms delivering consistent clinical and financial outcomes.
CRVL's robust financial profile—featuring a debt-free balance sheet, $233 million in cash, $66 million in free cash flow (up $7 million YoY), and improved operating margin of 15% (up 140 bps YoY)—combined with disciplined capital allocation through its share repurchase program (now having repurchased 69% of total shares outstanding at an average price of $7.70) signals strong confidence in intrinsic value and provides significant flexibility for strategic acquisitions or accelerated technological investment, particularly as management explicitly noted the balance sheet uniquely positions the company for accelerating product expansion and acquisition opportunities, a lever that could meaningfully accelerate growth beyond organic expectations if deployed toward adjacent technology-enabled claims management assets.
CRVL's reported double-digit revenue and profit growth in Network Solutions was significantly influenced by one-time events within CERIS, specifically accelerated post-payment recoveries from large payer engagement that management acknowledged as a timing-related benefit, which added $0.02 to EPS and may not be sustainable at current levels, raising concerns about the quality of underlying growth as the company's core Patient Management segment only delivered low single-digit revenue and profit growth, reflecting a stable but stagnant demand environment that suggests the overall business may be overly reliant on episodic, non-recurring wins in network solutions rather than broad-based, durable demand across its portfolio.
Despite management's emphasis on AI and automation as key differentiators, the company disclosed that personnel levels increased during the period to support service delivery and implementation activity, with normalization expected only as deployments mature and automation workflows are deployed through the remainder of the year and into 2027, indicating that near-term execution is still heavily reliant on manual labor and that the promised productivity gains from technology investments remain future-oriented and unproven at scale, creating execution risk if integration delays occur or if AI-driven workflow enhancements fail to deliver the anticipated reduction in reliance on manual processes, thereby pressuring operating leverage.
CRVL operates in an environment of rising claims severity, increased medical costs, and greater complexity driven by an aging workforce and expanded behavioral health considerations, yet the company did not quantify how its clinically driven utilization management or bundled care models are mitigating these cost pressures, nor did it provide evidence that its connected interface platform is demonstrably improving outcomes at a scale sufficient to justify premium pricing, leaving it vulnerable to payer pushback on pricing in an environment where cost containment remains a paramount priority, especially if competitors offer comparable technology-enabled solutions at lower cost or if regulatory scrutiny increases on algorithmic decision-making in claims processing.
CRVL's reported double-digit revenue and profit growth in Network Solutions was significantly influenced by one-time events within CERIS, specifically accelerated post-payment recoveries from large payer engagement that management acknowledged as a timing-related benefit, which added $0.02 to EPS and may not be sustainable at current levels, raising concerns about the quality of underlying growth as the company's core Patient Management segment only delivered low single-digit revenue and profit growth, reflecting a stable but stagnant demand environment that suggests the overall business may be overly reliant on episodic, non-recurring wins in network solutions rather than broad-based, durable demand across its portfolio.
Despite management's emphasis on AI and automation as key differentiators, the company disclosed that personnel levels increased during the period to support service delivery and implementation activity, with normalization expected only as deployments mature and automation workflows are deployed through the remainder of the year and into 2027, indicating that near-term execution is still heavily reliant on manual labor and that the promised productivity gains from technology investments remain future-oriented and unproven at scale, creating execution risk if integration delays occur or if AI-driven workflow enhancements fail to deliver the anticipated reduction in reliance on manual processes, thereby pressuring operating leverage.
CRVL operates in an environment of rising claims severity, increased medical costs, and greater complexity driven by an aging workforce and expanded behavioral health considerations, yet the company did not quantify how its clinically driven utilization management or bundled care models are mitigating these cost pressures, nor did it provide evidence that its connected interface platform is demonstrably improving outcomes at a scale sufficient to justify premium pricing, leaving it vulnerable to payer pushback on pricing in an environment where cost containment remains a paramount priority, especially if competitors offer comparable technology-enabled solutions at lower cost or if regulatory scrutiny increases on algorithmic decision-making in claims processing.